In a prespecified secondary analysis of MAPLE-HCM (165 of 175 analysed), aficamten vs metoprolol for 24 weeks in symptomatic obstructive HCM improved VE/VCO2 slope (−2.8), anaerobic threshold (+76 mL/min), peak workload (+8 W) and circulatory power.
Secondary analysisn = 175
Lewis et al. Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial